1. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
    Yusuke Takushima et al, 2021, Japanese Journal of Clinical Oncology CrossRef
  2. Value-Based Analysis of Therapies in Refractory Metastatic Colorectal Cancer in US
    Sang Kyu Cho et al, 2022, Clinical Colorectal Cancer CrossRef
  3. Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer
    K. Zhou et al, 2020, Clinical and Translational Oncology CrossRef
  4. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
    Anuj K. Patel et al, 2020, The Oncologist CrossRef
  5. Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
    Jiayun Zhong et al, 2024, Cancer Management and Research CrossRef
  6. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer
    Julia Martinez-Perez et al, 2018, Expert Opinion on Drug Safety CrossRef
  7. Cost-effectiveness indicator for colorectal cancer therapy
    E. V. Eliseeva et al, 2020, Pacific Medical Journal CrossRef
  8. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece
    George Gourzoulidis et al, 2019, Journal of Comparative Effectiveness Research CrossRef
  9. Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan
    Munenobu Kashiwa et al, 2020, Clinical Therapeutics CrossRef
  10. Trifluridine/tipiracil in metastatic colorectal cancer: a guide to its use
    Katherine A. Lyseng-Williamson et al, 2017, Drugs & Therapy Perspectives CrossRef
  11. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States
    Sang Kyu Cho et al, 2018, Clinical Colorectal Cancer CrossRef
  12. Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study
    Federica Martorana et al, 2017, AIMS Medical Science CrossRef